S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
The gold catalyst we’ve waited for (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The gold catalyst we’ve waited for (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Buy THIS stock before Taiwan is attacked (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
The gold catalyst we’ve waited for (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The gold catalyst we’ve waited for (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Buy THIS stock before Taiwan is attacked (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
The gold catalyst we’ve waited for (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The gold catalyst we’ve waited for (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Buy THIS stock before Taiwan is attacked (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
The gold catalyst we’ve waited for (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The gold catalyst we’ve waited for (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Buy THIS stock before Taiwan is attacked (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
NYSE:LLY

Eli Lilly and - LLY Stock Forecast, Price & News

$334.60
-1.53 (-0.46%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$323.26
▼
$336.22
50-Day Range
$310.63
▼
$357.74
52-Week Range
$276.83
▼
$384.44
Volume
3.10 million shs
Average Volume
3.23 million shs
Market Capitalization
$317.97 billion
P/E Ratio
48.49
Dividend Yield
1.35%
Price Target
$382.05

Eli Lilly and MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
14.2% Upside
$382.05 Price Target
Short Interest
Healthy
0.96% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.25
Upright™ Environmental Score
News Sentiment
0.57mentions of Eli Lilly and in the last 14 days
Based on 31 Articles This Week
Insider Trading
Selling Shares
$68.89 M Sold Last Quarter
Proj. Earnings Growth
36.28%
From $8.49 to $11.57 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.12 out of 5 stars

Medical Sector

22nd out of 995 stocks

Pharmaceutical Preparations Industry

5th out of 482 stocks

See Top Rated MarketRank™ Stocks Here

LLY stock logo

About Eli Lilly and (NYSE:LLY) Stock

Eli Lilly and Company is a US-based multinational pharmaceutical company. It is the 12th largest pharmaceutical company by revenue and has offices in 16 countries. Its medicines are sold in at least 125 countries including its 8 blockbuster drugs. The company is a member of the S&P 500 and S&P 100 indices, it brought in roughly $5.5 billion in revenue for 2021 and employs more than 35,000 people across its network of research and production facilities.

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The colonel, a veteran of the Civil War, had recently dissolved an unsatisfactory partnership and set on his own to produce and develop medicinal chemicals. Colonel Lilly remained as president until his death in 1898. His charge to his family, company and coworkers was to “take what you find here and make it better and better”. The company is well-known for many drugs, including the first mass-marketing of quinine to treat malaria.

The company brought in $4,470 in its first year and saw that figure grow 10X over the next 3. Among the many innovations during this time period is the addition of gelation coatings for pills which helped set the company up for rapid expansion. The company was incorporated in 1881 as Eli Lilly and Company issuing stock to family and friends. The 1900s brought about more change for the company, change in the form of expansion which included international markets.

Advancements during the war years included increases in efficiency due to increased automation and the development of precision technologies. Among the technologies was pill manufacturing which included injecting medicines directly into a gelation capsule. This method allowed for more exact dosing, setting the standard for modern production. The company produced capsules for itself and sold excess capacity to competitors. Other major advancements include fruit flavorings in medicine, straight-line manufacturing and a method of blueprinting manufacturing tickets to prevent errors.

The modern period saw the company grow and discover new, world-class pharmaceuticals. Today, the company is engaged in the discovery, development and marketing of human pharmaceuticals. It offers a wide range of treatments, including Prozac but is perhaps most noteworthy for its work with insulin. The company is the first to mass produce insulin and has made numerous advances in treating diabetes in the time since. While other drugs are more widely known, its diabetic drugs Basaglar, Jardience, Trulicity, Humalog and Humulin are its top-sellers and contribute the bulk of revenue and cash flow.

Along with Diabetic research, the company also focuses on Alzheimer's, Oncology, Immunology, Obesity and Pain care. At the end of 2022, the company pipeline had 23 compounds in Phase 3 clinical trials and 1 in review. There were another 18 in Phase 2 trials and more than 2 dozen in Phase 1 trials. The average cost to discover a new drug was running at $2.6 billion with a 10-year discovery-to-patient timeline.

Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and and its competitors with MarketBeat's FREE daily newsletter.

LLY Stock News Headlines

March 8, 2023 | marketbeat.com
Schrodinger is an AI-Powered Drug Discovery Developer to Watch (LLY)
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117
March 28, 2023 | marketwatch.com
Geriatric Medicines Market Growth and Forecast till 2028
March 28, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
March 27, 2023 | marketwatch.com
2023-2029 Kinase Inhibitors Market Size (Share and Outlook) with Comprehensive Regional Analysis | Research Report by Absolute Reports
March 27, 2023 | msn.com
Eli Lilly to create 1,500 jobs with $1bn investment in Limerick facility
March 27, 2023 | msn.com
Will Chart Analysts Notice Bad Omen on Eli Lilly's Chart
March 27, 2023 | finance.yahoo.com
Novartis Surges As It Goes After Eli Lilly's Second Biggest Moneymaker
March 26, 2023 | americanbankingnews.com
Brokerages Set Eli Lilly and Company (NYSE:LLY) PT at $382.05
March 28, 2023 | Investor Place Media (Ad)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
March 24, 2023 | marketwatch.com
Fibromyalgia Treatment Market 2023 Size and Forecast to 2030
March 24, 2023 | finance.yahoo.com
US FDA seeks more rigorous trials for cancer drugs' accelerated nod
March 24, 2023 | finance.yahoo.com
If EPS Growth Is Important To You, Eli Lilly (NYSE:LLY) Presents An Opportunity
March 24, 2023 | finance.yahoo.com
The Zacks Analyst Blog Highlights Lilly, Honeywell International. American Express, Lowe's Companies and Airbnb
March 23, 2023 | fool.com
Will Eli Lilly Be a Trillion-Dollar Stock by 2030?
March 23, 2023 | marketwatch.com
Clinical Trials Market 2023 Size and Forecast to 2030
March 23, 2023 | seekingalpha.com
Eli Lilly: Best-Now Near-Term Price Gains Pharmaceuticals Stock
March 22, 2023 | msn.com
Alzheimer’s Blood Test That Could Help Diagnose Disease Earlier Is Being Developed By Eli Lilly And Roche
March 22, 2023 | wsj.com
Eli Lilly Is Priced for Perfection in the Obesity Market
March 22, 2023 | markets.businessinsider.com
Roche, Lilly To Develop Elecsys Amyloid Plasma Panel To Boost Early Diagnosis Of Alzheimer's Disease
March 22, 2023 | msn.com
Lilly, Roche team up to develop blood test for Alzheimer's disease
March 22, 2023 | bizjournals.com
Pfizer, Lilly, Novartis invest in two-year-old Third Rock spinout
March 22, 2023 | finance.yahoo.com
Roche teams up with Lilly to validate Alzheimer's blood test
March 22, 2023 | forbes.com
Is Bristol Myers Squibb Stock A Better Pick Over Its Industry Peer?
March 21, 2023 | marketwatch.com
Atomoxetine Market Growth Factors Details for Business Development 2023 to 2030 | Eli Lilly and Company, Apotex, Aurobindo, Glenmark
March 21, 2023 | marketwatch.com
Injection Pen Market Outlook and Forecast till 2028
March 20, 2023 | msn.com
Novo Nordisk Joins Eli Lilly in Reducing Insulin List Prices—Here’s Everything You Need To Know
March 18, 2023 | msn.com
Sanofi announces insulin price cap after actions by Ely Lilly and Novo Nordisk
See More Headlines
Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and and its competitors with MarketBeat's FREE daily newsletter.

LLY Company Calendar

Last Earnings
2/02/2023
Ex-Dividend for 3/10 Dividend
2/14/2023
Dividend Payable
3/10/2023
Today
3/28/2023
Next Earnings (Confirmed)
4/27/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NYSE:LLY
CUSIP
53245710
CIK
59478
Web
www.lilly.com
Phone
(317) 276-2000
Fax
317-276-4878
Employees
39,000
Year Founded
1876

Price Target and Rating

Average Stock Price Forecast
$382.05
High Stock Price Forecast
$444.00
Low Stock Price Forecast
$278.00
Forecasted Upside/Downside
+14.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
14 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$6.90
Trailing P/E Ratio
48.49
Forward P/E Ratio
39.41
P/E Growth
1.92
Net Income
$6.24 billion
Net Margins
21.88%
Pretax Margin
23.85%
Return on Equity
73.61%
Return on Assets
15.06%

Debt

Debt-to-Equity Ratio
1.37
Current Ratio
1.05
Quick Ratio
0.80

Sales & Book Value

Annual Sales
$28.54 billion
Price / Sales
11.14
Cash Flow
$9.12 per share
Price / Cash Flow
36.67
Book Value
$11.34 per share
Price / Book
29.51

Miscellaneous

Outstanding Shares
950,300,000
Free Float
949,156,000
Market Cap
$317.97 billion
Optionable
Optionable
Beta
0.36

Social Links


Key Executives

  • David A. RicksDavid A. Ricks
    Chairman, President & Chief Executive Officer
  • Ruth Gimeno
    Vice President
  • Anat AshkenaziAnat Ashkenazi
    Chief Financial Officer & Senior Vice President
  • Daniel M. SkovronskyDaniel M. Skovronsky
    Chief Scientific Officer & Senior Vice President
  • Diogo Rau
    Senior VP, Chief Information & Digital Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













LLY Stock - Frequently Asked Questions

Should I buy or sell Eli Lilly and stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LLY shares.
View LLY analyst ratings or view top-rated stocks.

What is Eli Lilly and's stock price forecast for 2023?

14 Wall Street research analysts have issued 12 month price objectives for Eli Lilly and's shares. Their LLY share price forecasts range from $278.00 to $444.00. On average, they expect the company's share price to reach $382.05 in the next year. This suggests a possible upside of 14.2% from the stock's current price.
View analysts price targets for LLY or view top-rated stocks among Wall Street analysts.

How have LLY shares performed in 2023?

Eli Lilly and's stock was trading at $365.84 at the start of the year. Since then, LLY shares have decreased by 8.5% and is now trading at $334.60.
View the best growth stocks for 2023 here.

Are investors shorting Eli Lilly and?

Eli Lilly and saw a increase in short interest in March. As of March 15th, there was short interest totaling 8,120,000 shares, an increase of 19.2% from the February 28th total of 6,810,000 shares. Based on an average daily volume of 3,020,000 shares, the days-to-cover ratio is presently 2.7 days. Currently, 1.0% of the shares of the company are sold short.
View Eli Lilly and's Short Interest.

When is Eli Lilly and's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our LLY earnings forecast.

How can I listen to Eli Lilly and's earnings call?

Eli Lilly and will be holding an earnings conference call on Thursday, April 27th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Eli Lilly and's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) issued its quarterly earnings results on Thursday, February, 2nd. The company reported $2.09 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.26. The company earned $7.30 billion during the quarter, compared to the consensus estimate of $7.39 billion. Eli Lilly and had a net margin of 21.88% and a trailing twelve-month return on equity of 73.61%. The company's revenue was down 8.7% on a year-over-year basis. During the same quarter last year, the business earned $2.49 earnings per share.
Read the conference call transcript.

How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?

Eli Lilly and declared a quarterly dividend on Monday, December 12th. Shareholders of record on Wednesday, February 15th will be paid a dividend of $1.13 per share on Friday, March 10th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 1.35%. The ex-dividend date of this dividend is Tuesday, February 14th. This is a positive change from the stock's previous quarterly dividend of $0.98.
Read our dividend analysis for LLY.

What ETFs hold Eli Lilly and's stock?

ETFs with the largest weight of Eli Lilly and (NYSE:LLY) stock in their portfolio include iShares U.S. Pharmaceuticals ETF (IHE), Harbor Health Care ETF (MEDI), Invesco Dynamic Pharmaceuticals ETF (PJP), Health Care Select Sector SPDR Fund (XLV), VanEck Pharmaceutical ETF (PPH), iShares U.S. Healthcare ETF (IYH), iShares MSCI USA Momentum Factor ETF (MTUM) and Fidelity MSCI Health Care Index ETF (FHLC).

Is Eli Lilly and a good dividend stock?

Eli Lilly and (NYSE:LLY) pays an annual dividend of $4.52 per share and currently has a dividend yield of 1.34%. The company has been increasing its dividend for 9 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 65.51%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LLY will have a dividend payout ratio of 39.07% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LLY.

How will Eli Lilly and's stock buyback program work?

Eli Lilly and announced that its board has approved a stock buyback program on Monday, May 3rd 2021, which allows the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 2.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.

What guidance has Eli Lilly and issued on next quarter's earnings?

Eli Lilly and issued an update on its FY23 earnings guidance on Thursday, February, 2nd. The company provided EPS guidance of $8.35-$8.55 for the period, compared to the consensus EPS estimate of $8.31. The company issued revenue guidance of $30.3-$30.8 billion, compared to the consensus revenue estimate of $30.57 billion.

What is David A. Ricks' approval rating as Eli Lilly and's CEO?

399 employees have rated Eli Lilly and Chief Executive Officer David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among the company's employees.

What other stocks do shareholders of Eli Lilly and own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

What is Eli Lilly and's stock symbol?

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Who are Eli Lilly and's major shareholders?

Eli Lilly and's stock is owned by a number of institutional and retail investors. Top institutional investors include Lilly Endowment Inc. (10.83%), PNC Financial Services Group Inc. (5.48%), Price T Rowe Associates Inc. MD (2.39%), Geode Capital Management LLC (1.55%), Morgan Stanley (1.27%) and Jennison Associates LLC (1.10%). Insiders that own company stock include Aarti S Shah, Acquisition Corp Kearny, Alfonso G Zulueta, Alonzo Weems, Anne E White, Donald A Zakrowski, Ilya Yuffa, Jackson P Tai, Lilly Endowment Inc, Marschall S Runge, Melissa S Barnes and Stephen F Fry.
View institutional ownership trends.

How do I buy shares of Eli Lilly and?

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eli Lilly and's stock price today?

One share of LLY stock can currently be purchased for approximately $334.60.

How much money does Eli Lilly and make?

Eli Lilly and (NYSE:LLY) has a market capitalization of $317.97 billion and generates $28.54 billion in revenue each year. The company earns $6.24 billion in net income (profit) each year or $6.90 on an earnings per share basis.

How many employees does Eli Lilly and have?

The company employs 39,000 workers across the globe.

Does Eli Lilly and have any subsidiaries?
The following companies are subsidiares of Eli Lilly and: 1096401 B.C. Unlimited Liability Company, ARMO Biosciences Inc., Acanthas Pharma Inc., Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma Inc., Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Compania Farmaceutica Eli Lilly de Centro America S.A., Dermira, Dermira Canada, Dermira Inc., Devices for Vascular Intervention(DVI), Disarm Therapeutics, Disarm Therapeutics, Disarm Therapeutics Inc., Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc., Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, LDH I Corporation, Lilly (Shanghai) Management Co. Ltd., Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly Centre for Clinical Pharmacology PTE. LTD., Lilly China Research and Development Co. Ltd, Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Loxo Oncology Inc., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Petra Pharma Corporation, Pharmaserve-Lilly S.A.C.I., Pharmaserve-Lilly S.A.C.I., Physio-Control, Prevail Therapeutics Inc., Protomer Technologies, SGX Pharmaceuticals, SGX Pharmaceuticals Inc., Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.
Read More
How can I contact Eli Lilly and?

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The official website for the company is www.lilly.com. The company can be reached via phone at (317) 276-2000, via email at johnson_philip_l@lilly.com, or via fax at 317-276-4878.

This page (NYSE:LLY) was last updated on 3/28/2023 by MarketBeat.com Staff